Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH): AST2303 tablets receive approval for drug clinical trials.
Ails (688578.SH) announced recently that the company has received the approval and issuance of the "Drug Clinical ..." by the National Medical Products Administration.
Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH) announced that the company recently received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration, approving the clinical trial of AST2303 tablets in adult patients with advanced non-small cell lung cancer carrying the EGFR C797S mutation. The announcement states that AST2303 tablets (ABK3376 tablets) are a highly selective and brain-permeable new generation EGFR oral small molecule inhibitor that can effectively inhibit the EGFRC797S mutation.
Related Articles
Midea Group Co., Ltd (00300) spent 40.0165 million yuan on September 9 to repurchase 467,900 A-shares.
NEWBORNTOWN (09911) spent approximately HKD 1,978,900 to repurchase 226,000 shares on September 9.
NANHUA FUTURES (02691) spent HKD 1.2333 million to buy back 177,000 shares on September 9.
Midea Group Co., Ltd (00300) spent 40.0165 million yuan on September 9 to repurchase 467,900 A-shares.
NEWBORNTOWN (09911) spent approximately HKD 1,978,900 to repurchase 226,000 shares on September 9.
NANHUA FUTURES (02691) spent HKD 1.2333 million to buy back 177,000 shares on September 9.
RECOMMEND
